March 12, 2018 / 11:39 AM / 7 months ago

BRIEF-Arrowhead Begins Dosing In Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

March 12 (Reuters) - Arrowhead Pharmaceuticals Inc:

* ARROWHEAD BEGINS DOSING IN PHASE 1 STUDY OF ARO-AAT FOR TREATMENT OF ALPHA-1 LIVER DISEASE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below